Study wrapper · #1335
Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.
Editor's note
This is a signal-prioritisation exercise, not a risk estimate, and the authors say so explicitly: spontaneous-reporting data cannot yield incidence, causality or comparative risk. The notable pattern is how much of the reported burden is medication-use error rather than classic pharmacology, with incorrect dose administered, extra dose administered and off-label use among the most common terms. Tirzepatide's share reflects uptake and reporting behaviour as much as anything intrinsic to the molecule. Read it as a map of where postmarketing attention is concentrated.
Plain-language abstract
Researchers pooled 243,114 U.S. adverse-event reports naming a GLP-1 drug as the primary suspect between early 2021 and early 2026, then cross-checked them against Canadian reports, FDA labelling changes and Medicaid dispensing data. The most frequent reports were dosing errors, nausea, injection-site pain, diarrhoea and vomiting, with tirzepatide accounting for 133,100 records and semaglutide 55,619. The authors stress these counts show where to look, not how often problems actually occur.